

Newsletter

Seventh Issue - January 2026



Welcome to the new issue of the METHYLOMIC Project Newsletter!

We are excited to share updates on our progress with all our stakeholders. This newsletter will be released quarterly to keep everyone informed about significant developments and achievements within our consortium.

The OMICROHN and EIPSORA clinal trials: update

The METHYLOMIC project is carrying on the OMICROHN and EIPSORA clinical trials. These groundbreaking studies aim to explore the use of epigenetic markers to improve treatment decisions in Crohn's disease, Psoriasis, and Rheumatoid Arthritis.

Both the OMICROHN and EIPSORA trials continue to make excellent progress:

- over 80 patients recruited in the OMICROHN trial;
- and over 110 patients recruited in the EIPSORA trial.



Funded by the
European Union

The project leading to this publication/presentation has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101095449



If you would like to learn more about the OMICROHN study and how to participate, please visit our project [webpage](#) or [IFCCA's webpage](#).

More information about the EIPSORA study is also available on our project [webpage](#).

METHYLOMIC documentary

Do not miss the newly released **two episodes of the METHYLOMIC documentary**, created with our project partner IFCCA (the International Federation of Crohn's & Ulcerative Colitis Associations). You can **watch them** [here](#).

These short videos bring the METHYLOMIC project and the OMICROHN study to life, explaining the science in an accessible way. We combined voices of researchers, clinicians, and patient representatives to show how epigenetic research could help shape more personalized care for people living with inflammatory bowel disease (IBD).

METHYLOMIC stakeholder workshop

If you missed IFCCA's workshop ***"What's Right for Me?" Precision Medicine in IBD*** held on 10 December 2025, you can still watch the recording [here](#).

In this workshop, Antonella Cardone, Dr. Virginia Solitano (San Raffaele Hospital), Dr Andrew Li Yim (Amsterdam UMC), Roberto Saldaña (IFCCA), Debra Montague (Lung Cancer Europe), and Cândida Cruz (IFCCA) explored how precision medicine is moving from theory to real benefit for people living with IBD, exchanged perspectives, and learned from one another.

Engage with us

Visit our website and follow us on social media for all the latest updates and exciting news.

Sharing our content helps support our mission and spread the word about our groundbreaking work in medical research.





We thank all our partners and collaborators for their continued support and dedication to the METHYLOMIC project. Together, we are paving the way for more personalized and effective care for patients.



Funded by the
European Union

The project leading to this publication/presentation has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101095449